Share our mission of improving patients’ lives.

At Sutro, we believe that meaningful innovation in oncology happens through partnerships. We approach collaborations with a clear vision: to accelerate the advancement of transformative cancer therapies that address significant unmet needs. Our unique cell-free protein synthesis platform enables rapid, precise design and scalable manufacturing of complex biologics, opening doors to groundbreaking possibilities. By partnering with Sutro, you gain access to cutting-edge science, deep technical expertise, and a team committed to turning ambitious ideas into impactful therapies.

Please contact us at bd@sutrobio.com

Our agreement with Astellas exemplifies how true innovation is achieved through partnership. In 2022, we entered into a worldwide, strategic collaboration and licensing agreement with Astellas focused on the discovery and development of novel dual-payload immunostimulatory antibody-drug conjugates (iADCs). The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise. 

Together, we turn bold science into better outcomes for patients.